Community Practice Connections™: Cases and Conversations: Exploring the Implications of Variants of Unknown Significance (VUS) in Fabry Disease

Released On
May 21, 2021

Expires On
May 21, 2022

Media Type

Completion Time
60 minutes

Cardiology, Genetics, Nephrology, Pediatrics

Genetic disorders, Heart Disease, Kidney disease, Pain, Pediatrics, Storage diseases

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Amicus Therapeutics.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward geneticists, genetic counselors, pediatricians, endocrinologists, primary care physicians, nurses, nurse practitioners, and physician assistants who treat patients with Fabry disease. Other health care professionals interested in the treatment of Fabry disease are also invited to participate.

Activity Overview

Fabry disease is a rare, X-linked lysosomal storage disease (LSD) resulting from pathogenic mutations in the α-galactosidase A gene (GLA). A wide variety of clinical manifestations and phenotypes with potentially life-threatening complications can develop, creating a considerable disease burden in this patient population.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a symposium on Fabry disease held at the American College of Medical Genetics (ACMG) 2021 annual meeting. This unique and engaging multimedia activity is ideal for community-based clinicians, geneticists, genetic counselors, and other health care professionals. This program focuses on the practical aspects of managing patients with Fabry disease, including pathogenesis, diagnosis, genotypic and phenotypic spectrums, current and emerging therapies, and advances in patient care. This program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the known pathophysiological mechanisms involved in Fabry disease, particularly the role of both typical and atypical genetic mutations in determining disease phenotype
  • Recognize the clinical features of both classic Fabry disease and nonclassic disease variants, including disease-related organ complications and other clinical implications
  • Select appropriate screening and diagnostic assessments for early disease recognition and incorporate evidence-based guidelines for monitoring and referral into clinical decision-making
  • Apply knowledge of data from research studies evaluating currently available treatments and considering their appropriateness for individual patients based on genotype, phenotype, family history, gender, and disease severity



Dawn Jacob Laney, MS, CGC, CCRC

Assistant Professor/Genetic Counselor
Director, Emory Genetic Clinical Trials Center
Program Leader, Emory Lysosomal Storage Disease Center
Emory University
Atlanta, GA


Anjay Rastogi, MD, PhD

Professor and Clinical Chief
Division of Nephrology | Department of Medicine
Director, UCLA CORE Kidney Program
Director, Nephrology Clinical Research Program
Director, Genetics in Kidney Disease
David Geffen School of Medicine at UCLA
UCLA Health
Los Angeles, CA


Robert Hopkin, MD

Associate Professor of Clinical Pediatrics
Director of the Genetics Residency Programs at Cincinnati Children’s Hospital Medical Center
Cincinnati Children’s Hospital Medical Center Division of Human Genetics
Cincinnati, OH

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Disclosures of Conflicts of Interest

Dawn Jacob Laney, MS, CGC, CCRC

  • Grant/Research Support: 4D Molecular Therapeutics, Amicus Therapeutics, Protalix BioTherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda/Shire
  • Consultant: Amicus Therapeutics, Protalix BioTherapeutics, Sanofi Genzyme, Takeda/Shire
  • Other: Cofounder, ThinkGenetic; serves on the Fabry Registry Board of Advisors.

Anjay Rastogi, MD, PhD

  • Grant/Research Support: Alnylam Pharmaceuticals, Bayer, Gilead, GlaxoSmithKline, Idorsia Pharmaceuticals, Kadmon Corporation, NIH, Novo Nordisk, Omeros, Pfizer, Protalix BioTherapeutics, Reata Pharmaceuticals, Summit Oxford
  • Consultant: Akebia, Ardelyx, AstraZeneca, Aurinia, Chiesi Global Inc, Fresenius Medical Care-Vifor, GlaxoSmithKline, Otsuka, Vifor Pharma (Relypsa), Sanofi S.A.
  • Speakers’ Bureau: Amgen, AstraZeneca, Aurinia, Baxter, Fresenius Medical Care, Janssen, Otsuka, Relypsa, Natera, Sanofi Genzyme, Spire Learning, Tricida.

Robert Hopkin, MD

  • Grant/Research Support: Alexion Pharmaceuticals, Amicus Therapeutics, Idorsia Pharmaceuticals, Protalix BioTherapeutics, Sanofi Genzyme, Takeda
  • Consultant: AVROBIO, Alexion Pharmaceuticals, Amicus Therapeutics, Chiesi USA, Sangamo Therapeutics, Sanofi Genzyme, Takeda
  • Speakers’ Bureau: Alexion Pharmaceuticals, Sanofi Genzyme
  • Other: Advisory Arrangement: Alexion Pharmaceuticals, Amicus Therapeutics, Sanofi Genzyme.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.